Reports Q3 revenue $0 vs. $366,000 last year. Revenue decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical...
Source LinkReports Q3 revenue $0 vs. $366,000 last year. Revenue decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.